In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA to buy Serono for CHF16.6bn

Executive Summary

Merck KGAA has agreed to acquire Geneva-based biotech Serono SA in a deal valued at CHF16.6bn ($12.9bn). Merck will initially buy out majority shareholders the Bertarelli family, which accounts for a 64.5% stake in Serono; the company plans to continue with a public tender offer in 2007 to acquire the remaining shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies